Results 351 to 360 of about 411,291 (407)

Primary Percutaneous Coronary Intervention in Single Ostium Coronary Arteries: Challenges and Considerations. [PDF]

Cureus
Saleem MW, Ullah S, Zaib UK, Amjad M, Ullah I, Khan MI.   +5 more
europepmc   +1 more source

Coronary ischemia and percutaneous intervention [PDF]

Cardiovascular Pathology, 2010
The interventional treatment of ischemia is a complex issue grounded on an understanding of basic pathophysiology, but translated and implemented in practice by extensive clinical trial data representing patients with a spectrum of ischemia-causing clinical syndromes and anatomical variations of coronary artery disease (CAD).
Michael S. Kim, Paul A. Hudson, John D. Carroll   +2 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Journal of the American Medical Association (JAMA), 2002
CONTEXT Following percutaneous coronary intervention (PCI), short-term clopidogrel therapy in addition to aspirin leads to greater protection from thrombotic complications than aspirin alone. However, the optimal duration of combination oral antiplatelet
S. Steinhubl, Peter B. Berger, J. Tift Mann III, Edward T. A. Fry, A. Delago, C. Wilmer, E. J. Topol   +6 more
semanticscholar   +1 more source

Recent advances in percutaneous coronary intervention

Heart, 2020
Percutaneous coronary intervention (PCI) continues to advance at pace with an ever-broadening indication. In this article we will review the recent technological advances in PCI that have enabled more complex coronary disease to be treated. The choice of
S. Hoole, P. Bambrough
semanticscholar   +1 more source

Is facilitated percutaneous coronary intervention superior to primary percutaneous coronary intervention? [PDF]

Nature Clinical Practice Cardiovascular Medicine, 2006
Is facilitated percutaneous coronary intervention superior to primary percutaneous coronary intervention?
openaire   +2 more sources

Cangrelor in percutaneous coronary intervention

Expert Review of Clinical Pharmacology, 2009
Cangrelor is a novel, intravenous P2Y12 receptor antagonist in development for use in percutaneous coronary intervention. Currently in Phase III testing, the reversible platelet inhibitor provides several inherent advantages over other P2Y12 receptor antagonists in this setting for the prevention of adverse cardiac events.
Julie H. Oestreich, Steven R. Steinhubl
openaire   +3 more sources

Percutaneous Coronary Intervention

2016
There are over one million percutaneous coronary interventions (PCI) performed each year in the United States. PCI refers to catheter- based procedures that allow for improved perfusion through epicardial coronary arteries to the myocardium. PCI originally referred to percutaneous transluminal coronary angioplasty, a solely balloon-based procedure, but
Manny C. Katsetos, Yousef Bader, Carey Kimmelstiel   +2 more
openaire   +2 more sources